Kamada reports record nine-month revenue, raises 2026 guidance and declares $0.14 dividend
The Israeli plasma-derived therapeutics company cites U.S. KEDRAB sales as the main driver of $152.2 million in nine-month revenue and now expects 2026 revenue of $205-208 million.
Kamada reported record results for the first nine months of 2026 on 9 November. Revenues came to $152.2 million and adjusted EBITDA to $40.9 million. The company attributed the performance mainly to U.S. sales of KEDRAB, together with VARIZIG and HEPAGAM.
On the back of these results, Kamada raised its full-year 2026 guidance. It now expects revenues of $205-208 million and adjusted EBITDA of $52-54 million. It also projected double-digit growth in 2027, without giving further detail in the material available to us.
The board declared a dividend of $0.14 per share, amounting to about $8.0 million in total.
Kamada also noted new biosimilar launches in Israel. It said it has enough KEDRAB supply to meet higher U.S. demand following a Health Advisory from the U.S. Centers for Disease Control and Prevention (CDC). The summary does not specify the subject of the advisory or the size of any demand increase.
Why it matters
- Supply teams and payers in the U.S. can note Kamada's statement that KEDRAB availability is sufficient to meet higher demand after the CDC Health Advisory.
- Market-access teams may want to watch how the company's biosimilar launches in Israel develop, as the source gives few details on products or timing.
- The raised 2026 guidance and projected double-digit growth in 2027 indicate continued commercial focus on the company's U.S. specialty plasma-derived products.
Company's press release (SEC filing): Kamada Ltd ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
